Clinical trials in Madrid – page 82

3 294 clinical trials in Madrid, Spain across 24 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in SpainEnsayosClinicos.es

Madrid at a glance

3 294

clinical trials

Research sites24

Quick filters

3 294 trials in Madrid

Open in trial search

Neoplasm

Recruiting

Study of INBRX-109 with Irinotecan Hydrochloride Trihydrate and Temozolomide for Patients with Advanced Solid Tumors, Including Sarcomas

Registered drugNo placebo

Study of INBRX-109 with Irinotecan Hydrochloride Trihydrate and Temozolomide for Patients with Advanced Solid Tumors, Including Sarcomas

Registered drugNo placebo

Spain

Participants:0–17 years · 18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Inhibrx Biosciences Inc.

Contact Research Centre

B-cell type acute leukaemia

Recruiting

Study on the Safety and Effectiveness of AZD0486 and Tocilizumab for Adolescents and Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Registered drugNo placebo

Study on the Safety and Effectiveness of AZD0486 and Tocilizumab for Adolescents and Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Registered drugNo placebo

Spain

Participants:0–17 years · 18–64 years · 65+ years
Substances:Tocilizumab
Sponsor:AstraZeneca AB

Contact Research Centre

Plasma cell myeloma

Recruiting

Study Comparing Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel or Stem Cell Transplant for Newly Diagnosed Multiple Myeloma Patients

Registered drugNo placebo

Study Comparing Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel or Stem Cell Transplant for Newly Diagnosed Multiple Myeloma Patients

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Contact Research Centre

Neoplasm

Recruiting

Study of Patritumab Deruxtecan for Patients with Advanced or Metastatic Solid Tumors

InvestigationalNo placebo

Study of Patritumab Deruxtecan for Patients with Advanced or Metastatic Solid Tumors

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Patritumab Deruxtecan
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Plasma cell myeloma refractory

Recruiting

Study Comparing Elranatamab to Drug Combinations for Patients with Relapsed/Refractory Multiple Myeloma After Anti-CD38 Therapy

Registered drugNo placebo

Study Comparing Elranatamab to Drug Combinations for Patients with Relapsed/Refractory Multiple Myeloma After Anti-CD38 Therapy

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Pfizer Inc.

Contact Research Centre

Relapsing multiple sclerosis+2

Recruiting

Study on Long-Term Safety of Tolebrutinib and Teriflunomide for Patients with Multiple Sclerosis

Registered drug

Study on Long-Term Safety of Tolebrutinib and Teriflunomide for Patients with Multiple Sclerosis

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Teriflunomide
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Pulmonary resection

Recruiting

Study on Lidocaine and Magnesium Sulfate for Patients Undergoing Lung Surgery with Video-Assisted Thoracic Surgery (VATS)

Registered drug

Study on Lidocaine and Magnesium Sulfate for Patients Undergoing Lung Surgery with Video-Assisted Thoracic Surgery (VATS)

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Sodium Chloride
Sponsor:Clinica Universidad De Navarra

Contact Research Centre

Colorectal cancer+1

Recruiting

Study on the Effectiveness of Heated Chemotherapy with Mitomycin-C for Patients with Colon Cancer Spread to the Peritoneum After Surgery

Registered drugNo placebo

Study on the Effectiveness of Heated Chemotherapy with Mitomycin-C for Patients with Colon Cancer Spread to the Peritoneum After Surgery

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Mitomycin
Sponsor:Hospital Universitario De Fuenlabrada

Contact Research Centre

Acute lymphocytic leukaemia

Recruiting

Infusion Study of ARI-0001 Cells for Patients with Resistant or Refractory CD19+ Acute Lymphoid Leukemia

Registered drugNo placebo

Infusion Study of ARI-0001 Cells for Patients with Resistant or Refractory CD19+ Acute Lymphoid Leukemia

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Allopurinol
Sponsor:Fundacio De Recerca Clinic Barcelona-Institut D’investigacions Biomediques August Pi I Sunyer

Contact Research Centre

Hormone receptor positive breast cancer

Recruiting

Study Comparing MK-2870 and Pembrolizumab with Chemotherapy for Patients with Advanced Hormone Receptor Positive Breast Cancer

Registered drugNo placebo

Study Comparing MK-2870 and Pembrolizumab with Chemotherapy for Patients with Advanced Hormone Receptor Positive Breast Cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Chronic lymphocytic leukaemia+1

Recruiting

Study on Lisaftoclax and Acalabrutinib for Patients with Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo

Study on Lisaftoclax and Acalabrutinib for Patients with Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Acalabrutinib
Sponsor:Ascentage Pharma Group Inc.

Contact Research Centre

Plasma cell myeloma

Recruiting

Study on the Safety and Effectiveness of AZD0305 Alone and with Other Cancer Drugs for Adults with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

Study on the Safety and Effectiveness of AZD0305 Alone and with Other Cancer Drugs for Adults with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Azd0305
Sponsor:AstraZeneca AB

Contact Research Centre

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Madrid

What the registry says about research in the country

01 Autoimmune and Inflammatory Conditions

Investigating novel treatments for cutaneous lupus erythematosus and immune thrombocytopenia, with studies evaluating new therapeutic approaches to manage these challenging conditions.

Lupus skin manifestations
Platelet disorders
Immune system regulation

Research focuses on improving treatment outcomes and quality of life for patients with autoimmune disorders.

02 Metabolic and Endocrine Disorders

Clinical trials examining innovative therapies for Type 1 Diabetes in combination with weight management, targeting both glycemic control and obesity-related complications.

Diabetes management
Weight control
Metabolic health

Studies aim to develop comprehensive treatment approaches for complex metabolic conditions.

03 Neurological Conditions

Breakthrough research in multiple sclerosis and acute ischemic stroke, exploring new therapeutic options for both pediatric and adult populations.

MS treatment in young patients
Stroke intervention
Neurological recovery

Focus on developing targeted treatments to improve neurological outcomes and patient care.

04 Infectious Disease Prevention

Comprehensive vaccine studies targeting respiratory syncytial virus, influenza, and herpes zoster, with particular attention to vulnerable populations.

Vaccine development
Immune response
Prevention strategies

Research aims to enhance protection against common and serious infectious diseases.

05 Oncology Research

Innovative studies in mantle cell lymphoma and bladder cancer, exploring combination therapies and targeted treatments to improve patient outcomes.

Lymphoma treatment
Bladder cancer therapy
Immunotherapy approaches

Focus on developing more effective and personalized cancer treatments.

Back to Spain All countries